{"filing":{"accession_number":"0001520138-26-000312","cik":"0001580149","ticker":"BIVIW","company_name":"BIOVIE INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"bivi-20260806_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1580149/000152013826000312/bivi-20260806_8k.htm"},"events":[{"id":25803,"run_id":23423,"accession_number":"0001520138-26-000312","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"BioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early-stage Parkinson's disease, showing statistically significant improvements on motor and non-motor symptoms, favorable biomarker changes, and a safety profile comparable to placebo. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's viability and the company's prospects, but it does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant clinical trial result that informs future development decisions.","company_name":"BIOVIE INC.","ticker":"BIVIW","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26723,"accession_number":"0001520138-26-000312","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early-stage Parkinson's disease, showing statistically significant improvements on motor and non-motor symptoms, favorable biomarker changes, and a safety profile comparable to placebo. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's viability and the company's prospects, but it does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant clinical trial result that informs future development decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:34:49.741696+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26723,"accession_number":"0001520138-26-000312","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"BioVie announced topline results from its Phase 2 SUNRISE-PD trial of bezisterim in early-stage Parkinson's disease, showing statistically significant improvements on motor and non-motor symptoms, favorable biomarker changes, and a safety profile comparable to placebo. This is a material clinical development milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's viability and the company's prospects, but it does not fit the earnings_release category (which typically applies to financial results) nor any other specific event type. The disclosure is clearly operational/strategic in nature—a significant clinical trial result that informs future development decisions.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:34:49.741696+00:00","company_name":"BIOVIE INC.","ticker":"BIVIW","filing_date":"2026-08-06"}]}